Evidence map›Paper›PMID 28411830›Full record

ArticleThe Journal of investigative dermatology2017

Leveraging Molecular Data Analysis to Understand Drug Response in Systemic Sclerosis.

Antonio Julià

Abstract readComment
PubMed Publisher
In one paragraph

Article in The Journal of investigative dermatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Antonio JuliàVall d'Hebron Hospital Research Institute, Rheumatology Research Group, Barcelona, Spain. Electronic address: toni.julia@vhir.org.
Vall d'Hebron Institut de Recerca · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Taroni et al. integrate and analyze genomic information generated from different clinical trials on systemic sclerosis, a disease for which there is yet no Food and Drug Administration-approved therapy. By using a recent network analysis approach based on tissue-specific functionality, they leverage the biological information extracted from molecular profiling studies and report findings that could be useful for patient stratification.

Indexed as

GenomicsHumansScleroderma, Systemic

Identifiers

PMID28411830
OpenAlexW2605961909

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.